Scientific Sessions 2024  /  Obesity and HFpEF: From Mechanisms to Management  /  Are incretin analogues the next STEP for HFpEF management in obesity?
Logo

American Heart Association

  2
  0

Final ID:

Are incretin analogues the next STEP for HFpEF management in obesity?

  • Kosiborod, Mikhail  ( ST LUKES HEALTH SYSTEM , Kansas City , Missouri , United States )
  • Butler, Javed  ( Baylor , Dallas , Texas , United States )
    • Author Disclosures:
    Mikhail Kosiborod: DO have relevant financial relationships ; Consultant:35Pharma, Imbria Pharmaceuticals:Active (exists now) ; Consultant:Esperion Therapeutics, Structure Therapeutics:Active (exists now) ; Consultant:Eli Lilly, scPharmaceuticals:Active (exists now) ; Consultant:Dexcom, Sanofi, Youngene Therapeutics:Active (exists now) ; Consultant:Cytokinetics, Regeneron:Active (exists now) ; Consultant:Boehringer Ingelheim:Active (exists now) ; Research Funding (PI or named investigator):Boehringer Ingelheim:Active (exists now) ; Consultant:Bayer, Pharmacosmos:Active (exists now) ; Other (please indicate in the box next to the company name):AstraZeneca, Vifor Pharma - data analytic center fees:Active (exists now) ; Consultant:AstraZeneca, Pfizer, Vifor Pharma:Active (exists now) ; Research Funding (PI or named investigator):AstraZeneca, Pfizer:Active (exists now) ; Consultant:Arrowhead Pharmaceuticals:Active (exists now) ; Consultant:Applied Therapeutics:Active (exists now) ; Consultant:Amgen, NovoNordisk:Active (exists now) ; Consultant:Alnylam, Merck (Diabetes and Cardiovascular):Active (exists now) | Javed Butler: DO have relevant financial relationships ; Consultant:Abbott, American Regent, Amgen, Applied Therapeutic,:Active (exists now) ; Speaker:Novartis, Boehringer Ingelheim-Lilly, Astra Zeneca, Impulse Dynamics, Vifor:Active (exists now) ; Consultant:Sequana, SQ Innovation, Tenex, Tricog, Ultromics, Vifor, and Zoll:Active (exists now) ; Consultant:Roche, Salamandra, Sanofi, SC Pharma, Secretome,:Active (exists now) ; Consultant:Pharmain, Pfize, Prolaio, Regeneron, Renibus,:Active (exists now) ; Consultant:Novartis, Novo Nordisk, Pfizer, Pharmacosmos,:Active (exists now) ; Consultant:Janssen, Medtronics, Merck, Occlutech, Owkin,:Active (exists now) ; Consultant:Inventiva, Ionis, Lexicon, Lilly, LivaNova,:Active (exists now) ; Consultant:Innolife, Impulse Dynamics, Imbria,:Active (exists now) ; Consultant:Faraday, Foundry, G3P,:Active (exists now) ; Consultant:Daxor, Edwards, Element Science,:Active (exists now) ; Consultant:Cardiorem, CSL Bearing, CVRx, Cytokinetics:Active (exists now) ; Consultant:Bristol Myers Squibb, Cardiac Dimension, Cardiocell, Cardior,:Active (exists now) ; Consultant:Bayer, Boehringer Ingelheim, Boston Scientific,:Active (exists now) ; Consultant:AskBio, Astellas, AstraZeneca,:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Obesity and HFpEF: From Mechanisms to Management

Saturday, 11/16/2024 , 01:30PM - 02:45PM

Cardiovascular Seminar

More abstracts on this topic:
The diagnostic approach to HFpEF in obesity

Sarma Satyam, Sharma Kavita

Multisystem pathology of HFpEF in obesity

Shah Sanjiv, Lewis Gregory, Sauer Andrew

More abstracts from these authors:
Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients with Heart Failure with Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial

Kosiborod Mikhail

The evolving therapeutic landscape in obesity and the effect on cardiovascular outcomes

Kosiborod Mikhail

You have to be authorized to contact abstract author. Please, Login
Not Available